Revolution Medicines Inc (RVMD)

$190.95 -5.99 (-3.04%)
Market Cap 41.99B
Revenue (ttm) 0.00
Net Income (ttm) -1.13B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.40
Volume 5,934,885
Avg Vol 1,775,124
Day's Range N/A - N/A
Shares Out 214.34M
Stochastic %K 17%
Beta 1.40
Analysts Strong Sell
Price Target $247.48

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6801
Address:
700 Saginaw Drive, Redwood City, United States
Alt_Fuel
Alt_Fuel Sep. 18 at 8:38 AM
$VSTM $RVMD 02595.HK Zhitong Finance reports that Jingfang Pharma-B (02595) announced on September 17, 2026, that the company repurchased 63,000 shares at a cost of approximately HK$1.5738 million, with repurchase prices ranging from HK$24.78 to HK$25.10 per share. https://www.moomoo.com/news/post/76406255/jinfang-medicine-b-02595-repurchased-63000-shares-for-approximately-hk?chain_id=bJoStPvEgQD6bO.1laptrf&futusource=news_web_stockpagenews&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22mm%2Fstock%2F02595-HK%2Fnews%22%7D&lang=en-us&ns_stock_id=87363929770531&report_id=73012749&report_type=stock&src=43&stock_news_tab=news&level=1&data_ticket=1761581596149365 (GenFleet Therapeutics / Jingfang Medicine-B) Listing Date: September 19, 2025 (IPO price HK$20.39) Core Focus: Differentiated therapies targeting RAS mutations, oncology, and autoimmune indications💡 Recent Developments & Pipeline GFH375: Its oral KRAS G12D inhibitor secured China's first Breakthrough Therapy Designation for non-small cell lung cancer (NSCLC). Share Repurchases: The company actively repurchased shares, including 63,000 shares for roughly HK$1.57 million on September 17, 2026, following prior buybacks in September.
0 · Reply
WillieMays
WillieMays Sep. 17 at 9:35 PM
$IMRX (Atebi) and $RVMD (Daraxon) both in Phase 3 for 1L Daraxon is already approved for 2L Assume both have comparable positive outcomes Doesn’t the scenario of Atebi in 1L followed by Daraxon in 2L make more sense than: Daraxon in 1L and no 2L option
1 · Reply
AppleStar
AppleStar Sep. 17 at 8:43 PM
$RVMD The future looks lovely… Recent individual targets (newest first) • LifeSci Capital — $315 (Buy, Sep 14, 2026)  • Stifel — $230 (Buy; raised from $215, Sep 9–13, 2026)  • Morgan Stanley — $255 (Overweight / Buy; initiated Sep 10, 2026)  • Needham — $275 (Buy; raised from $240, Aug 31, 2026) • Guggenheim — $275 (Buy; raised from $240, Aug 28, 2026) • UBS — $265 (Buy; raised from $220, Aug 28, 2026) • Evercore ISI — $320 (Outperform / Buy; raised, Aug 27, 2026) • HC Wainwright — $280 (Buy; raised from $195, Aug 27, 2026) • Oppenheimer — $260 (Outperform; raised from $230, Aug 27, 2026) • RBC Capital — $251 (Outperform; raised from $203, Aug 27, 2026) • Wedbush — $225 (Buy; raised, Aug 27, 2026) • Truist — $239 (Buy / Strong Buy; raised from $231, Aug 27, 2026) • Jefferies — $270 (Buy)
0 · Reply
Ne54467
Ne54467 Sep. 17 at 8:12 PM
$RVMD motley says buy the dip. this was your dip.
0 · Reply
CaliBull64
CaliBull64 Sep. 17 at 5:58 PM
$RVMD why has this pulled back so drastically since formal fda approval?
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 17 at 4:24 PM
RAS inhibitors and PRP are designed to address different layers of tumor biology. $RVMD and $ERAS target oncogenic RAS signaling. PRP takes a different approach—targeting EMT, cancer stem cells and the tumor microenvironment, mechanisms associated with resistance, recurrence, and metastasis. For $PPCB, this creates a scientific rationale for exploring PRP alongside or following RAS-targeted therapies. As the RAS field expands, PRP’s differentiated mechanism could open multiple development paths—from combination to sequential or maintenance approaches. Different mechanisms. Potentially complementary roles. A broader opportunity as the treatment landscape evolves. $PPCB $RVMD $ERAS
1 · Reply
The_Blue_Print
The_Blue_Print Sep. 17 at 1:56 PM
$KURA $RVMD on its way. Potential 3x with good read out results.
0 · Reply
Alt_Fuel
Alt_Fuel Sep. 17 at 8:59 AM
$VSTM $RVMD BOCOM International Holdings Company Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595) - September 17, 2026 at 4:25 AM NOTE - Verastem License Agreement: Verastem exercised its first exclusive license option for VS-7375 in January 2025, securing global development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan (which are retained by GenFleet). https://www.tipranks.com/news/blurbs/bocom-international-holdings-company-reaffirms-their-buy-rating-on-genfleet-therapeutics-shanghai-inc-class-h-2595-blurbs-news
1 · Reply
The_Blue_Print
The_Blue_Print Sep. 17 at 3:32 AM
$KURA read outs coming soon. The next $RVMD and my followers know what happened there. From $40 to $224. 6x
1 · Reply
AppleStar
AppleStar Sep. 16 at 10:13 PM
$RVMD Stephen Kelsey had a pre-planned Rule 10b5-1 sale. The Form 4 and Form 144 both state the trades were made under a 10b5-1 plan he adopted on June 12, 2026. Kelsey is in a leadership transition—he moved from President of R&D to senior advisor to the CEO as of July 1 and has a planned retirement date of January 4, 2027—so option exercises and diversification around that timeline are common.
2 · Reply
Latest News on RVMD
Revolution Medicines gets orphan designation for pancreatic cancer treatment

2026-09-15T19:00:13.000Z - 3 days ago

Revolution Medicines gets orphan designation for pancreatic cancer treatment

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

2026-09-14T20:15:36.000Z - 4 days ago

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Sep 14, 2026, 4:05 PM EDT - 4 days ago

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Revolution Medicines initiated with an Overweight at Morgan Stanley

2026-09-10T09:45:13.000Z - 8 days ago

Revolution Medicines initiated with an Overweight at Morgan Stanley

Revolution Medicines price target raised to $230 from $215 at Stifel

2026-09-09T11:40:56.000Z - 9 days ago

Revolution Medicines price target raised to $230 from $215 at Stifel

New drug shows promise for lung cancer

Sep 6, 2026, 6:00 AM EDT - 12 days ago

New drug shows promise for lung cancer

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

Sep 5, 2026, 5:00 AM EDT - 13 days ago

Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.

MRNA

NEJM publishes Phase 1/2 clinical data on daraxonrasib

2026-09-02T21:55:16.000Z - 16 days ago

NEJM publishes Phase 1/2 clinical data on daraxonrasib

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Sep 2, 2026, 5:50 PM EDT - 16 days ago

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines price target raised to $275 from $240 at Needham

2026-08-31T11:15:49.000Z - 18 days ago

Revolution Medicines price target raised to $275 from $240 at Needham

Revolution Medicines price target raised to $265 from $220 at UBS

2026-08-28T11:20:17.000Z - 21 days ago

Revolution Medicines price target raised to $265 from $220 at UBS

Revolution Medicines price target raised to $275 from $240 at Guggenheim

2026-08-28T11:10:31.000Z - 21 days ago

Revolution Medicines price target raised to $275 from $240 at Guggenheim

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Aug 27, 2026, 9:21 PM EDT - 21 days ago

Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent

Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug

2026-08-27T16:14:22.000Z - 22 days ago

Revolution Medicines Stock (RVMD) Gets Price Target Hike on New Revenue-Generating Cancer Drug

Revolution Medicines price target raised to $246 from $227 at JPMorgan

2026-08-27T13:15:56.000Z - 22 days ago

Revolution Medicines price target raised to $246 from $227 at JPMorgan

Revolution Medicines price target raised to $251 from $203 at RBC Capital

2026-08-27T12:55:22.000Z - 22 days ago

Revolution Medicines price target raised to $251 from $203 at RBC Capital

Revolution Medicines price target raised to $248 from $230 at Raymond James

2026-08-27T12:36:41.000Z - 22 days ago

Revolution Medicines price target raised to $248 from $230 at Raymond James

Revolution Medicines price target raised to $260 from $230 at Oppenheimer

2026-08-27T12:15:09.000Z - 22 days ago

Revolution Medicines price target raised to $260 from $230 at Oppenheimer

Revolution Medicines price target raised to $320 from $230 at Evercore ISI

2026-08-27T11:55:59.000Z - 22 days ago

Revolution Medicines price target raised to $320 from $230 at Evercore ISI

Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright

2026-08-27T10:10:11.000Z - 22 days ago

Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

2026-08-26T17:45:20.000Z - 23 days ago

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

Revolution Medicines Transcript: FDA announcement

Aug 26, 2026, 1:30 PM EDT - 23 days ago

Revolution Medicines Transcript: FDA announcement

Revolution Medicines Slides: FDA announcement

Aug 26, 2026, 1:30 PM EDT - 23 days ago

Revolution Medicines Slides: FDA announcement

Revolution Medicines Press release: FDA announcement

Aug 26, 2026, 1:30 PM EDT - 23 days ago

Revolution Medicines Press release: FDA announcement

Revolution Medicines announces FDA approval of Rasonque in adults

2026-08-26T17:05:25.000Z - 23 days ago

Revolution Medicines announces FDA approval of Rasonque in adults

U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Aug 26, 2026, 12:59 PM EDT - 23 days ago

U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval

2026-08-26T16:04:40.000Z - 23 days ago

Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.

Aug 26, 2026, 11:37 AM EDT - 23 days ago

Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.

The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis

Aug 26, 2026, 11:18 AM EDT - 23 days ago

The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Aug 26, 2026, 11:08 AM EDT - 23 days ago

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

Revolution Medicines price target raised to $179 from $151 at Bernstein

2026-08-21T11:25:09.000Z - 4 weeks ago

Revolution Medicines price target raised to $179 from $151 at Bernstein

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Aug 10, 2026, 6:00 AM EDT - 5 weeks ago

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

ONC

Revolution Medicines Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 6 weeks ago

Revolution Medicines Earnings Call Transcript: Q2 2026

Revolution Medicines Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 6 weeks ago

Revolution Medicines Earnings release: Q2 2026

Revolution Medicines Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 6 weeks ago

Revolution Medicines Quarterly report: Q2 2026

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Aug 5, 2026, 4:02 PM EDT - 6 weeks ago

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 6 weeks ago

Revolution Medicines Slides: Corporate presentation

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

Jul 29, 2026, 4:05 PM EDT - 7 weeks ago

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

Jul 22, 2026, 4:05 PM EDT - 1 month ago

Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

Jul 7, 2026, 9:23 AM EDT - 2 months ago

European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill

Jul 7, 2026, 9:09 AM EDT - 2 months ago

EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Jul 2, 2026, 8:00 AM EDT - 2 months ago

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Jun 24, 2026, 7:31 PM EDT - 2 months ago

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Jun 1, 2026, 6:34 AM EDT - 3 months ago

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

ONC SMMT

Revolution Medicines Transcript: Study result

May 31, 2026, 7:00 PM EDT - 3 months ago

Revolution Medicines Transcript: Study result

Revolution Medicines Slides: Study result

May 31, 2026, 7:00 PM EDT - 3 months ago

Revolution Medicines Slides: Study result

Revolution Medicines Press release: Study result

May 31, 2026, 7:00 PM EDT - 3 months ago

Revolution Medicines Press release: Study result

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

May 31, 2026, 8:06 AM EDT - 3 months ago

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

May 31, 2026, 8:02 AM EDT - 3 months ago

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

RVMDW

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

May 21, 2026, 4:05 PM EDT - 4 months ago

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

May 14, 2026, 6:04 AM EDT - 4 months ago

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

May 6, 2026, 6:00 PM EDT - 4 months ago

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

May 6, 2026, 5:01 PM EDT - 4 months ago

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

Revolution Medicines Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Revolution Medicines Earnings Call Transcript: Q1 2026

Revolution Medicines Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Revolution Medicines Earnings release: Q1 2026

Revolution Medicines Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Revolution Medicines Quarterly report: Q1 2026

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 6, 2026, 4:02 PM EDT - 4 months ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines Slides: Corporate presentation

May 6, 2026, 4:00 PM EDT - 4 months ago

Revolution Medicines Slides: Corporate presentation

US FDA authorizes early access to Revolution's pancreatic cancer pill

May 1, 2026, 12:54 PM EDT - 4 months ago

US FDA authorizes early access to Revolution's pancreatic cancer pill

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Apr 29, 2026, 4:05 PM EDT - 4 months ago

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Revolution Medicines Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Revolution Medicines Proxy statement: Proxy filing

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Apr 28, 2026, 5:30 AM EDT - 4 months ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Revolution Medicines Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Revolution Medicines Proxy statement: Proxy filing

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Apr 21, 2026, 5:35 PM EDT - 5 months ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Two experimental drugs showed striking early results against pancreatic cancer

Apr 21, 2026, 5:35 PM EDT - 5 months ago

Two experimental drugs showed striking early results against pancreatic cancer

BNTX

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Apr 21, 2026, 5:30 PM EDT - 5 months ago

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

ON

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Apr 21, 2026, 11:23 AM EDT - 5 months ago

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

Apr 19, 2026, 2:00 PM EDT - 5 months ago

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 17, 2026, 4:02 PM EDT - 5 months ago

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

This Pill May Help Pancreatic Cancer Patients Live Longer

Apr 15, 2026, 12:10 PM EDT - 5 months ago

This Pill May Help Pancreatic Cancer Patients Live Longer

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Apr 15, 2026, 12:41 AM EDT - 5 months ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Apr 13, 2026, 4:01 PM EDT - 5 months ago

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Apr 13, 2026, 10:13 AM EDT - 5 months ago

Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.

Apr 13, 2026, 9:45 AM EDT - 5 months ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.

This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.

Apr 13, 2026, 9:11 AM EDT - 5 months ago

This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.

Revolution Medicines' experimental cancer pill helps improve survival in late-stage study

Apr 13, 2026, 8:06 AM EDT - 5 months ago

Revolution Medicines' experimental cancer pill helps improve survival in late-stage study

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Apr 10, 2026, 1:49 PM EDT - 5 months ago

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Mar 17, 2026, 6:37 PM EDT - 6 months ago

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Revolution Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 9:50 AM EST - 6 months ago

Revolution Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025

Revolution Medicines Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Revolution Medicines Annual report: Q4 2025

Revolution Medicines Earnings release: Q4 2025

Feb 25, 2026, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings release: Q4 2025

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb 25, 2026, 4:02 PM EST - 6 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Slides: Corporate presentation

Feb 25, 2026, 7:00 AM EST - 6 months ago

Revolution Medicines Slides: Corporate presentation

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:05 PM EST - 6 months ago

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb 18, 2026, 4:05 PM EST - 7 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Revolution Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:30 AM EST - 7 months ago

Revolution Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 7 months ago

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Overlooked Stock: RVMD Sells After MRK Turns Away

Jan 26, 2026, 4:30 PM EST - 7 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK

Alt_Fuel
Alt_Fuel Sep. 18 at 8:38 AM
$VSTM $RVMD 02595.HK Zhitong Finance reports that Jingfang Pharma-B (02595) announced on September 17, 2026, that the company repurchased 63,000 shares at a cost of approximately HK$1.5738 million, with repurchase prices ranging from HK$24.78 to HK$25.10 per share. https://www.moomoo.com/news/post/76406255/jinfang-medicine-b-02595-repurchased-63000-shares-for-approximately-hk?chain_id=bJoStPvEgQD6bO.1laptrf&futusource=news_web_stockpagenews&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22mm%2Fstock%2F02595-HK%2Fnews%22%7D&lang=en-us&ns_stock_id=87363929770531&report_id=73012749&report_type=stock&src=43&stock_news_tab=news&level=1&data_ticket=1761581596149365 (GenFleet Therapeutics / Jingfang Medicine-B) Listing Date: September 19, 2025 (IPO price HK$20.39) Core Focus: Differentiated therapies targeting RAS mutations, oncology, and autoimmune indications💡 Recent Developments & Pipeline GFH375: Its oral KRAS G12D inhibitor secured China's first Breakthrough Therapy Designation for non-small cell lung cancer (NSCLC). Share Repurchases: The company actively repurchased shares, including 63,000 shares for roughly HK$1.57 million on September 17, 2026, following prior buybacks in September.
0 · Reply
WillieMays
WillieMays Sep. 17 at 9:35 PM
$IMRX (Atebi) and $RVMD (Daraxon) both in Phase 3 for 1L Daraxon is already approved for 2L Assume both have comparable positive outcomes Doesn’t the scenario of Atebi in 1L followed by Daraxon in 2L make more sense than: Daraxon in 1L and no 2L option
1 · Reply
AppleStar
AppleStar Sep. 17 at 8:43 PM
$RVMD The future looks lovely… Recent individual targets (newest first) • LifeSci Capital — $315 (Buy, Sep 14, 2026)  • Stifel — $230 (Buy; raised from $215, Sep 9–13, 2026)  • Morgan Stanley — $255 (Overweight / Buy; initiated Sep 10, 2026)  • Needham — $275 (Buy; raised from $240, Aug 31, 2026) • Guggenheim — $275 (Buy; raised from $240, Aug 28, 2026) • UBS — $265 (Buy; raised from $220, Aug 28, 2026) • Evercore ISI — $320 (Outperform / Buy; raised, Aug 27, 2026) • HC Wainwright — $280 (Buy; raised from $195, Aug 27, 2026) • Oppenheimer — $260 (Outperform; raised from $230, Aug 27, 2026) • RBC Capital — $251 (Outperform; raised from $203, Aug 27, 2026) • Wedbush — $225 (Buy; raised, Aug 27, 2026) • Truist — $239 (Buy / Strong Buy; raised from $231, Aug 27, 2026) • Jefferies — $270 (Buy)
0 · Reply
Ne54467
Ne54467 Sep. 17 at 8:12 PM
$RVMD motley says buy the dip. this was your dip.
0 · Reply
CaliBull64
CaliBull64 Sep. 17 at 5:58 PM
$RVMD why has this pulled back so drastically since formal fda approval?
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Sep. 17 at 4:24 PM
RAS inhibitors and PRP are designed to address different layers of tumor biology. $RVMD and $ERAS target oncogenic RAS signaling. PRP takes a different approach—targeting EMT, cancer stem cells and the tumor microenvironment, mechanisms associated with resistance, recurrence, and metastasis. For $PPCB, this creates a scientific rationale for exploring PRP alongside or following RAS-targeted therapies. As the RAS field expands, PRP’s differentiated mechanism could open multiple development paths—from combination to sequential or maintenance approaches. Different mechanisms. Potentially complementary roles. A broader opportunity as the treatment landscape evolves. $PPCB $RVMD $ERAS
1 · Reply
The_Blue_Print
The_Blue_Print Sep. 17 at 1:56 PM
$KURA $RVMD on its way. Potential 3x with good read out results.
0 · Reply
Alt_Fuel
Alt_Fuel Sep. 17 at 8:59 AM
$VSTM $RVMD BOCOM International Holdings Company Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595) - September 17, 2026 at 4:25 AM NOTE - Verastem License Agreement: Verastem exercised its first exclusive license option for VS-7375 in January 2025, securing global development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan (which are retained by GenFleet). https://www.tipranks.com/news/blurbs/bocom-international-holdings-company-reaffirms-their-buy-rating-on-genfleet-therapeutics-shanghai-inc-class-h-2595-blurbs-news
1 · Reply
The_Blue_Print
The_Blue_Print Sep. 17 at 3:32 AM
$KURA read outs coming soon. The next $RVMD and my followers know what happened there. From $40 to $224. 6x
1 · Reply
AppleStar
AppleStar Sep. 16 at 10:13 PM
$RVMD Stephen Kelsey had a pre-planned Rule 10b5-1 sale. The Form 4 and Form 144 both state the trades were made under a 10b5-1 plan he adopted on June 12, 2026. Kelsey is in a leadership transition—he moved from President of R&D to senior advisor to the CEO as of July 1 and has a planned retirement date of January 4, 2027—so option exercises and diversification around that timeline are common.
2 · Reply
EmSol
EmSol Sep. 16 at 9:32 PM
$RVMD added 500 shares 196.75
1 · Reply
EmSol
EmSol Sep. 16 at 9:31 PM
$RVMD
0 · Reply
Ne54467
Ne54467 Sep. 16 at 7:25 PM
$RVMD why did this drop so much today? just overall market sentiment?
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 16 at 6:16 PM
$JNJ $MRK $SLS $RVMD Excellent post Rob. I like to add earlier this year we saw $RVMD jump $30 Billion in MC after phase 3 and 2 big pharmaceuticals backed away from a deal. I don’t think they will make same mistake here with Sellas. ✌️🙏❤️‍🩹
0 · Reply
PhantomZ
PhantomZ Sep. 16 at 5:02 PM
$TLTFF $CGON $RVMD In light of the recent GLP study prior to commencing human trials here is a glimpse of the potential here. No other animal model achieved 100% CR complete response in MIBC, but Rutherrin did! https://theralase.com/theralaser-reports-complete-response-with-x-ray-activated-rutherrinr-in-muscle-invasive-bladder-cancer-preclinical-study/
1 · Reply
pont9
pont9 Sep. 16 at 2:37 AM
$RVMD i know its early but .. anyone know the numbers for Weekly/4-week TRx for daraxonrasib?
1 · Reply
PhantomZ
PhantomZ Sep. 16 at 12:13 AM
$MRK $PFE $RVMD $CGON $BMY many posssible combination with IV injected Rutherin when activated by X-rays increases Tumor cell kill 100 fold vs radiation therapy alone. newsfilecorp.com/release/31...
2 · Reply
BioRich
BioRich Sep. 15 at 10:40 PM
$DRTS Still my favorite cancer pick ($RVMD, no disrespect, but we all know you're amazing). New article out highlighting $DRTS and I think it's just the beginning of this next generation opportunity. From the article: "A head and neck cancer trial was stopped early because the results were so strong the study had already proven its point." (vs. $MRK Keytruda, alone) "A brain cancer study where two out of three patients saw their tumors disappear entirely." "A pancreatic cancer trial that expanded from 12 patients to 48 because so many doctors wanted their patients in it." "Alpha Tau Medical Ltd. (NASDAQ: DRTS) is generating a pattern of early clinical results that keep exceeding what the trials were designed to test, and the next few months could determine whether that pattern holds at scale." $XBI
1 · Reply
Alt_Fuel
Alt_Fuel Sep. 15 at 9:54 AM
$VSTM $RVMD $ERAS Verastem - GenFleet’s KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial - September 14, 2026 at 8:07 PM GenFleet’s oral KRAS G12D inhibitor GFH375 showed robust efficacy and manageable safety in pretreated NSCLC patients, supporting its move into the world’s first Phase III trial of an oral KRAS G12D inhibitor and reinforcing its Breakthrough Therapy status in China. High response and disease control rates, solid progression-free survival, and insights into safety risks after recent immunotherapy exposure bolster GenFleet’s RAS-focused oncology strategy and increase the strategic value of its ex-China partnership with Verastem. https://www.tipranks.com/news/company-announcements/genfleets-kras-g12d-lung-cancer-drug-shows-strong-phase-ii-results-advancing-to-first-global-phase-iii-trial
1 · Reply
Alt_Fuel
Alt_Fuel Sep. 14 at 10:02 PM
$VSTM $RVMD $ERAS Verastem - H.C. Wainwright Annual Global Investment Conference Webcast Presentation September 14, 2026 at 1:00 PM Listen to webcast https://investor.verastem.com/events/event-details/hc-wainwright-annual-global-investment-conference
0 · Reply
jhk35611
jhk35611 Sep. 14 at 8:59 PM
$SLS Today after close at 4:05pm $RVMD The FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) combined with chemotherapy for previously untreated, first-line metastatic pancreatic cancer. Revolution Medicines’ announcement⁠ 😎❤️🙏
2 · Reply
STACKD0E
STACKD0E Sep. 14 at 8:25 PM
$CTNM $AGMB $RVMD 👁
0 · Reply